Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 774

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 774
---
 Merger Agreement, the Company has entered into a Securities Purchase Agreement, dated as of April 16, 2025, by and among the Company, Merger Partner, Ligand, Nomis Bay Ltd., a Bermuda exempted company (“ Nomis Bay ”) and certain other investors acceptable to Nomis Bay (the “ Other Investors ” and collectively with Ligand and Nomis Bay, the “ Investors ”) attached hereto as Exhibit B (the “ Securities Purchase Agreement ”), providing for an aggregate commitment of not less than $50,000,000 in the Surviving Corporation, pursuant to which such Investors have agreed to purchase the number of Series A Preferred Shares immediately prior to the Effective Time (the “ Financing ”), which also contemplates that the Company will enter into a Registration Rights Agreement by and among the Company and the Investors attached hereto as Exhibit C (the “ Registration Rights Agreement ” and together with the Securities Purchase Agreement, the “ Financing Documents ”);

WHEREAS , pursuant to Section 78.140 of the NRS, no contract or transaction between a corporation and one or more of its directors or officers, or between a corporation another corporation, firm or association in which one or more of its directors or officers are directors or officers, or are financially interested, is void or voidable solely for this reason, or solely because the director or officer is present at the meeting of the board of directors or committee that authorizes the contract or transaction or joins tin the signing of a written consent which authorizes or approves the contract or transaction, or solely because any such director’s or officer’s votes are counted for the purpose of authorizing or approving the contract or transaction, if: (i) the fact of the common directorship, office or financial interest is known to the board of directors or committee, and the directors or members of the committee, other than any common or interested directors or members of the committee, approve or ratify the contract or transaction in good faith; (ii) the fact of the common directorship, office or financial interest is known to the stockholders, and stockholders holding a majority of the voting power approve or ratify the contract or transaction in good faith. the

<div align='center'>E-1</div>

#### TABLE OF CONTENTS
votes of the common or interested directors or officers must be counted in any such vote of stockholders; (iii) the fact of the common directorship, office or financial interest is not known to the director or officer at the time the transaction is